To the Editor We read with interest the meta-analysis by Duan et al1 assessing differences in outcomes between programmed cell death 1 (PD-1) vs programmed cell death ligand 1 (PD-L1) inhibitors in the treatment of patients with cancer. We agree that this is a clinically significant question for which indirect comparison may play a role in the absence of head-to-head trials. However, there were limitations to this analysis that, despite its compliance with PRISMA guidelines, suggest the authors’ conclusions (ie, superiority in efficacy of PD-1 over PD-L1 inhibitors) are not well supported.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ghiorghiu S, Mukhopadhyay P, Massacesi C. Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer. JAMA Oncol. Published online April 30, 2020. doi:10.1001/jamaoncol.2020.0637
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: